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Summary
 
TRAIL (tumor necrosis factor [TNF]-related apoptosis-inducing ligand) is a molecule that dis-
plays potent antitumor activity against selected targets. The results presented here demonstrate
that human monocytes rapidly express TRAIL, but not Fas ligand or TNF, after activation
with interferon (IFN)-
 
g
 
 or -
 
a
 
 and acquire the ability to kill tumor cells. Monocyte-mediated
tumor cell apoptosis was TRAIL specific, as it could be inhibited with soluble TRAIL recep-
tor. Moreover, IFN stimulation caused a concomitant loss of TRAIL receptor 2 expression,
which coincides with monocyte acquisition of resistance to TRAIL-mediated apoptosis. These
results define a novel mechanism of monocyte-induced cell cytotoxicity that requires TRAIL,
and suggest that TRAIL is a key effector molecule in antitumor activity in vivo.
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M
 
ononuclear phagocytes (M
 
f
 
)
 
1
 
 circulate in the periph-
eral blood before differentiation into non-lymphoid
and lymphoid tissue–associated macrophages (1). M
 
f
 
 medi-
ate several host defense mechanisms through activation of
MHC class I– and class II–restricted T lymphocytes (2, 3),
release of inflammatory mediators
 
 
 
(4), and killing of virus-
infected cells (5). In addition, M
 
f
 
 effectively kill tumor
cells through both antibody-dependent and antibody-inde-
pendent mechanisms (6, 7). A critical prerequisite for these
M
 
f
 
 functions is cellular activation. Two potent mediators
of M
 
f
 
 activation, IFN-
 
g 
 
and IFN-
 
a
 
, dramatically enhance
the cytolytic potential of human M
 
f
 
 (8, 9). The mecha-
nisms responsible for this IFN-induced tumoricidal activity
remain poorly defined. Nitric oxide (NO) is known to be
produced by M
 
f
 
 and is a potent mediator of tumor cell
death (10, 11). However, several reports have demonstrated
that IFN-
 
g
 
 and IFN-
 
a
 
 stimulation of human M
 
f
 
 does not
increase the level of NO release, suggesting that NO does
not play a significant role in the cytotoxic activity of IFN-
stimulated human M
 
f
 
 (12–14). Although TNF possesses
cytolytic activity and is produced by M
 
f
 
 after certain types
of activation (e.g., LPS), several studies have shown that
IFN does not induce TNF production in human M
 
f
 
 (15–
17). These data indicate that other cell death–inducing
molecules may be involved with the M
 
f
 
-mediated tumor-
icidal activity after IFN stimulation.
Two TNF family members capable of inducing cell death
are Fas ligand (FasL) and TNF-related apoptosis-inducing
ligand (TRAIL). FasL participates in many physiological
events, including autoimmunity, activation-induced cell death
(AICD) of lymphocytes, immune privilege, and tumor
evasion from the immune system (18–21). Dysregulation of
physiological Fas/FasL interactions results in immune dis-
ease states characterized by enhanced levels of Fas-mediated
apoptosis and a variety of forms of hepatitis (22–24) or dis-
eases with decreased levels of lymphocyte death (e.g.,
human autoimmune lymphoproliferative syndrome [18]).
Human M
 
f
 
 contain high levels of intracellular FasL that
can be released after cellular activation (25). Recent evi-
dence indicates that FasL-expressing M
 
f
 
 are essential in the
elimination of activated effector T cells in homeostasis and
in disease, suggesting that they may also play an important
physiological role in a variety of other immunological set-
tings (23, 26–29).
In contrast to FasL, the role of TRAIL in immune regu-
lation remains enigmatic (30). Recent studies have iden-
tified four distinct cell surface TRAIL receptors, with two
(DR4 and DR5/TRAIL-R2; hereafter referred to as
TRAIL-R1 and -R2, respectively) that contain a cytoplas-
mic death domain and signal for apoptotic cell death upon
receptor cross-linking, and two (TRID/DcR1/TRAIL-R3
and TRAIL-R4/DcR2; hereafter referred to as TRAIL-R3
and -R4, respectively) that lack a death domain, making
 
1
 
Abbreviations used in this paper:
 
 AICD, activation-induced cell death;
 
L-NMMA, 
 
N
 
G
 
-monomethyl-
 
l
 
-arginine; LZ, leucine zipper; M
 
f
 
, mono-
nuclear phagocyte(s); NO, nitric oxide; RT, reverse transcription;
TRAIL, TNF-related apoptosis-inducing ligand. 
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them unable to signal for cell death (31–37). Recombinant,
soluble forms of TRAIL are potent mediators of tumor cell
apoptosis, while demonstrating minimal cytotoxicity to-
ward normal tissues in vitro and in vivo (38–40). The cell
death induced by TRAIL displays many of the same char-
acteristics observed with other apoptotic molecules (i.e.,
FasL and TNF), such as caspase activation, DNA fragmen-
tation into oligonucleosomal “ladders,” annexin V binding,
and the morphological membrane blebbing and apoptotic
body release (30, 38, 41). This tumoricidal activity occurs
on 
 
z
 
2/3 of the 
 
.
 
30 hematopoietic and nonhematopoietic
tumor cell lines tested (30, 36, 38, 42). Such studies not
only support the potential use for TRAIL as an antitumor
therapeutic agent (30, 38, 40), but suggest that TRAIL may
be an innate effector molecule involved in the elimination
of a broad range of spontaneously arising tumor cells. The
results presented here identify a novel mechanism by which
M
 
f
 
 induce tumor cell apoptosis via TRAIL.
 
Materials and Methods
 
Reagents and mAbs.
 
Reagents and sources were as follows:
IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-15, GM-CSF (100 ng/ml;
Immunex); IFN-
 
a
 
, IFN-
 
g
 
, IL-10, IL-12 (100 ng/ml; Genzyme
Corp.); LPS (5 ng/ml; DIFCO); MOPC-21, nonspecific IgG1
isotype control; MOPC-173, nonspecific IgG2a isotype control;
M181, IgG1 anti-TRAIL (Immunex); mAb11, IgG1 anti-TNF;
NOK-1, IgG1 anti-FasL (PharMingen). The mAbs against the
four TRAIL receptors (M271, IgG2a anti–TRAIL-R1; M413,
IgG1 anti–TRAIL-R2; M430, IgG1 anti–TRAIL-R3; and M444,
IgG1 anti–TRAIL-R4) were produced at Immunex by immu-
nizing BALB/c mice (The Jackson Laboratory) with a purified
fusion protein consisting of the extracellular domain of human
TRAIL-R1, -R2, -R3, or -R4 coupled to the constant region of
human IgG1 (huTRAIL-R:Fc) in Titermax (CytRx Corpora-
tion). Mice were boosted three times, and spleen cells were fused
with the murine myeloma NS1 in the presence of 50% polyeth-
ylene glycol in PBS followed by culture in DMEM/HAT and
DMEM/HT selective media. Supernatants from positive wells
were tested for the ability to bind the appropriate TRAIL recep-
tor in an ELISA (cell-based ELISA using CV1 cells transfected
with TRAIL receptor cDNA) and reactivity to huTRAIL-R:Fc
in Western blots. Hybridomas that produced antibodies that
bound to huTRAIL-R:Fc, but not human IgG1, were cloned by
three rounds of limiting dilution. All mAbs were purified by pro-
tein A affinity chromatography. The matrix metalloproteinase in-
hibitors, TAPI (TNF protease inhibitor [43]) and KB8301, were
obtained from Immunex and PharMingen, respectively. The
soluble fusion proteins TRAIL-R2:Fc, Fas:Fc, and TNFR:Fc
were produced at Immunex. The leucine zipper (LZ)-TRAIL
expression plasmid (34) and the production and purification of
LZ-huTRAIL (40) have been described previously.
 
Cell Lines.
 
The ovarian carcinoma cell line (OVCAR3) was
obtained from Dr. Richard F. Camalier, Developmental Thera-
peutics Program, Division of Cancer Treatment and Diagnosis,
National Cancer Institute (Bethesda, MD). The human mela-
noma cell lines (WM 793 and 164) were obtained from Dr. M.
Herlyn, Wistar Institute (Philadelphia, PA). The human prostate
carcinoma cell line (PC-3) was obtained from Dr. Michael Co-
hen, University of Iowa (Iowa City, IA). The human colon car-
cinoma cell line (Colo205) and the human lung adenocarcinoma
 
cell line (H2126) were provided by Dr. Brian Gliniak and Tim
Lofton, respectively (Immunex). L929 cells and normal human
foreskin fibroblasts were obtained from American Type Culture
Collection. All tumor cell lines were cultured as directed. The
normal human lung fibroblasts were purchased from Clonetics
Corporation and cultured as directed.
 
Isolation of Human M
 
f
 
.
 
Peripheral blood M
 
f
 
 were enriched
using countercurrent elutriation. Cells from leukopheresis packs
obtained from healthy volunteers were loaded onto a JE-5 elutri-
ator (Beckman), and 50-ml fractions were collected while in-
creasing the flow rate from 65 to 85 ml/min at 2,000 rpm.
M
 
f
 
-enriched fractions generated from a flow rate 
 
.
 
75 ml/min
were 
 
.
 
90% CD14
 
1
 
 as assessed by flow cytometric analysis using
TUK-4, an IgG2a anti-CD14 (Caltag Laboratories, Inc.).
 
Flow Cytometry.
 
Untreated or cytokine-stimulated M
 
f
 
 were
incubated with the following unlabeled primary mAbs for 1 h at
4
 
8
 
C: MOPC-21, MOPC-173, M181, M271, M413, M430,
M444, mAb11, and NOK-1. After three washes, primary antibody
binding was detected with a PE-conjugated, Fc-specific, mouse
anti–human F(ab
 
9
 
)
 
2
 
 (Jackson ImmunoResearch Laboratories).
Staining for TNF was done in the presence of the matrix metal-
loproteinase inhibitor, TAPI (50 
 
m
 
M). Staining for FasL was
done in the presence of the matrix metalloproteinase inhibitor,
KB8301 (10 
 
m
 
M). Cells were analyzed immediately after staining
or fixed in 1% paraformaldehyde until analysis on a FACSCali-
bur™ (Becton Dickinson).
 
TRAIL-mediated Killing of Human Tumor Cells.
 
M
 
f
 
 were cul-
tured for 12 h in medium alone, GM-CSF, IFN-
 
g
 
, or IFN-
 
a
 
,
washed, and resuspended in complete medium. Tumor cells were
labeled with 100 
 
m
 
Ci of 
 
51
 
Cr for 1 h at 37
 
8
 
C, washed three times,
and resuspended in complete medium. To determine TRAIL-
induced death, 
 
51
 
Cr-labeled tumor cells (10
 
4
 
/well) were incu-
bated with varying numbers of M
 
f
 
 effector cells for 8 h. As a
positive control, soluble LZ-TRAIL was added to the target cells
at the indicated concentrations. In some cultures, TRAIL-R2:Fc,
Fas:Fc, or TNFR:Fc (20 
 
m
 
g/ml) was added to the M
 
f
 
 effector
cells 15 min before adding tumor cell targets. All cytotoxicity as-
says were performed in round-bottomed 96-well plates, and the
percent specific lysis was calculated as: 100 
 
3
 
 (experimental cpm 
 
2
 
spontaneous cpm)/(total cpm 
 
2
 
 spontaneous cpm). Spontaneous
and total release were determined in the presence of either
medium alone or 1% NP-40, respectively. The presence of
TRAIL-R2:Fc, Fas:Fc, or TNFR:Fc during the assay had no ef-
fect on the level of spontaneous release of 
 
51
 
Cr by the target cells.
For analysis of tumor cell apoptosis, tumor cell targets were incu-
bated with unstimulated or cytokine-stimulated M
 
f
 
 as described
above. Apoptotic cell death of the tumor cells was measured by
flow cytometry using FITC-conjugated annexin V and propi-
dium iodide (Apoptosis detection kit; R&D Systems) as per the
manufacturer’s protocol. Light scatter characteristics were used to
identify the tumor cells.
 
Inhibition of NO Synthesis.
 
The specific inhibitor of NO syn-
thase, 
 
N
 
G
 
-monomethyl-
 
l
 
-arginine (L-NMMA; AerBio, Ltd.),
was used to block M
 
f
 
 NO production (44). M
 
f
 
 were stimulated
with the appropriate cytokine and then incubated with the tumor
cell targets as above. M
 
f
 
 were cultured in the presence of 300 
 
m
 
M
L-NMMA at all steps throughout the assay. The presence of
L-NMMA had no effect on the level of spontaneous release of
 
51
 
Cr by the target cells during the assay.
 
TNF-mediated Killing of L929 Cells.
 
M
 
f
 
 were cultured for 2 or
12 h in medium alone or LPS (5 ng/ml), washed, and resuspended
in complete medium. L929 cells were labeled with 100 
 
m
 
Ci of
 
51
 
Cr for 1 h at 37
 
8
 
C, washed three times, and resuspended in com- 
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plete medium. To determine TNF-induced death, 
 
51
 
Cr-labeled
L929 cells (10
 
4
 
/well) were incubated with varying numbers of
M
 
f
 
 effector cells for 8 h. As a positive control, soluble TNF was
added to the target cells at the indicated concentrations. In some
cultures, TNFR:Fc or TRAIL-R2:Fc (20 
 
m
 
g/ml) was added to
the M
 
f
 
 effector cells 15 min before adding tumor cell targets.
L929 cytotoxicity assays were performed in an identical manner
as for the human tumor cell lines. The presence of TNFR:Fc or
TRAIL-R2:Fc during the assay had no effect on the level of
spontaneous release of 
 
51
 
Cr by the L929 target cells.
 
TRAIL-mediated Killing of M
 
f
 
.
 
M
 
f
 
 were cultured for 12 h
in medium alone or with cytokine (IL-1, IL-2, IL-3, IL-4, IL-7,
IL-10, IL-12, IL-15, GM-CSF, or IFN-
 
g
 
; all cytokines were used
at 100 ng/ml), and then labeled with 100 
 
m
 
Ci of 
 
51
 
Cr for 1 h at
37
 
8
 
C, washed three times, and resuspended in complete medium.
To determine sensitivity to TRAIL-induced death, 
 
51
 
Cr-labeled
M
 
f
 
 (10
 
6
 
/well) were incubated with LZ-TRAIL for 8 h. Assays
were performed as described above.
 
Reverse Transcription PCR.
 
Total RNA was isolated from M
 
f
 
with TRIzol reagent (Life Technologies) as per the manufacturer’s
instructions. RNA samples (1 
 
m
 
g each) were tested for DNA con-
tamination by 30 cycles of PCR with human 
 
b
 
-actin primers. Af-
ter it was shown that there was no DNA contamination, cDNA
synthesis was performed using an RNA PCR kit (Perkin-Elmer)
with the supplied oligo d(T)
 
16
 
 primer. Reverse transcription was
performed using a thermal program of 25
 
8
 
C for 10 min, 42
 
8
 
C for
30 min, and 95
 
8
 
C for 5 min. PCR reactions were performed using
the following primers: human 
 
b
 
-actin (forward: 5
 
9
 
-GAAACTAC-
CTTCAACTCCATC-3
 
9
 
; reverse: 5
 
9-CGAGGCCAGGATGGA-
GCCGCC-39); human TRAIL-R1 (forward: 59-CTGAGCAA-
CGCAGACTCGCTGTCCAC-39; reverse: 59-TCCAAGGACA-
CGGCAGAGCCTGTGCCAT-39); human TRAIL-R2 (for-
ward: 59-GCCTCATGGACAATGAGATAAAGGTGGCT-39;
reverse: 59-CCAAATCTCAAAGTACGCACAAACGG-39); hu-
man TRAIL-R3 (forward: 59-GAAGAATTTGGTGCCAAT-
GCCACTG-39; reverse: 59-CTCTTGGACTTGGCTGGGAGA-
TGTG-39); human TRAIL-R4 (forward: 59-CTTTTCCGG-
CGGCGTTCATGTCCTTC-39; reverse: 59-GTTTCTTCCA-
GGCTGCTTCCCTTTGTAG-39); and human TRAIL (for-
ward: 59-CAACTCCGTCAGCTCGTTAGAAAG-39; reverse:
59-TTAGACCAACAACTATTTCTAGCACT-39), giving prod-
ucts of 219, 506, 502, 612, 453, and 443 bp, respectively. b-actin
PCR cycle conditions were 958C for 45 s, 558C for 1 min, and
728C for 45 s for 30 cycles. TRAIL-R1, -R2, and -R3 cycle
conditions were 948C for 1 min, 558C for 1 min, and 728C for 1
min for 30 cycles. TRAIL-R4 cycle conditions were 958C for 4
min 15 s, followed by 30 cycles of 958C for 45 s, 608C for 45 s,
and 728C for 45 s. TRAIL cycle conditions were 958C for 45 s,
558C for 45 s, and 728C for 45 s for 30 cycles. Samples were re-
solved on a 2% agarose gel and visualized with ethidium bromide.
Results
Human Mf Stimulated with IFN Upregulate TRAIL.
To compare the difference in TRAIL, FasL, and TNF sur-
face expression, peripheral blood human Mf were isolated
and cultured with several molecules known to induce Mf
activation and differentiation (IFN-g, IFN-a, GM-CSF,
and LPS), and then examined by flow cytometry. Signifi-
cant TRAIL expression was detected on the Mf cultured
for 12 h in the presence of either IFN-g or IFN-a, but not
with either GM-CSF or LPS (Fig. 1 A). In contrast, FasL
expression on Mf was undetectable after either 2- or 12-h
stimulation with any of the cytokines or LPS in the pres-
ence of the metalloproteinase inhibitor, KB8301 (Fig. 1 A).
Analysis of the surface levels of TNF demonstrated no mea-
surable increase after stimulation with IFN-g or IFN-a;
however, stimulation with LPS for 2 h led to increased sur-
face levels of TNF that disappeared by 12 h (Fig. 1 B). To
inhibit the cleavage of membrane TNF, Mf were cultured
in the presence of the metalloproteinase inhibitor, TAPI
(TNF protease inhibitor [43]). These data demonstrate that
TRAIL, but not FasL and TNF, is induced after IFN stim-
ulation, and that the expression of TRAIL and TNF on
Mf is regulated by distinct activation stimuli and with dif-
ferent kinetics.
IFN-stimulated Mf Kill Tumor Cells via a TRAIL-depen-
dent Mechanism. The results from Fig. 1 demonstrate that
Mf stimulated with IFN upregulate the expression of TRAIL
Figure 1. TRAIL, FasL, and TNF ex-
pression on human Mf. (A) Mf were incu-
bated for 2 or 12 h in the absence or presence
of IFN-g, IFN-a, GM-CSF, or LPS and
then analyzed for TRAIL or FasL surface
expression. Filled histograms represent
staining at 12 h by either M181 (anti-
TRAIL mAb) or NOK-1 (anti-FasL mAb).
Open histograms represent staining at 2 h
with the same mAb, whereas dotted histo-
grams represent staining with isotype con-
trol mAb. (B) Mf were incubated as in A
and then analyzed for TNF surface expres-
sion. Filled histograms represent staining at
2 h by mAb11 (anti-TNF mAb). Open his-
tograms represent staining at 12 h with the
same mAb, whereas dotted histograms rep-
resent staining with isotype control mAb.
Histograms represent 104 gated Mf in all
conditions, and viability was .95% as as-
sessed by propidium iodide exclusion.
These observations were reproduced using
Mf from at least five different donors.1346 TRAIL-mediated Tumoricidal Activity by Human Monocytes
on the cell surface. Thus, to examine the functional activity
of TRAIL in this setting, Mf were stimulated with either
GM-CSF, IFN-g, or IFN-a for 12 h and then cultured in
the presence of OVCAR3, a TRAIL-sensitive human ova-
rian carcinoma cell line. Although the unstimulated or
GM-CSF–treated Mf demonstrated minimal tumoricidal
activity toward OVCAR3, the Mf stimulated with IFN-g
or IFN-a were potent killers of these TRAIL-sensitive tu-
mor cells over a broad range of E/T ratios (Fig. 2 A). A ti-
tration of both IFN-g and IFN-a concentrations revealed
that as little as 10 pg/ml led to enhanced Mf cytotoxicity
against the tumor cells; however, GM-CSF did not induce
any antitumor activity at any concentration tested (100 ng/ml
to 10 pg/ml; data not shown). Moreover, the IFN-stimu-
lated Mf were as effective in killing the tumor target cells as
recombinant, soluble TRAIL (LZ-TRAIL [34]). The tu-
moricidal activity of IFN-stimulated Mf was also examined
on a TRAIL-resistant human melanoma cell line, WM 164,
and a TRAIL-sensitive human melanoma cell line, WM 793
(38). The TRAIL-resistant melanoma (WM 164) was also
resistant to the Mf-mediated cytotoxicity, whereas the
TRAIL-sensitive melanoma (WM 793) was quite sensitive
to the cytotoxic activity of either IFN-g– or IFN-a–stimu-
lated Mf (Fig. 2, B and C). The tumoricidal activity of both
IFN-g– or IFN-a–stimulated Mf was seen from multiple
donors and with other TRAIL-sensitive tumor cells (Table
Figure 2. TRAIL-mediated
tumoricidal activity by human
Mf occurs after stimulation with
IFN. (A–D) Mf were incu-
bated for 12 h in the absence or
presence of either GM-CSF,
IFN-g, or IFN-a and then cul-
tured for 8 h with 51Cr-labeled
(A) OVCAR3, (B) WM 164, or
(C) WM 793 target cells at the
indicated E/T ratios. As a posi-
tive control, soluble LZ-TRAIL
(LZT) was added to target cells
at the indicated concentrations.
(D) Inclusion of the fusion pro-
tein TRAIL-R2:Fc (20 mg/ml) to
12-h IFN-g–stimulated Mf in-
hibited killing of WM 793 target
cells, whereas addition of Fas:Fc
(20 mg/ml) did not. (E and F)
Addition of the NO inhibitor
L-NMMA (300 mM) did not al-
ter the antitumor activity of (E)
IFN-g– or  (F) IFN-a–stimu-
lated Mf against WM 793 target
cells. Data points represent the
mean of triplicate wells, and ex-
periments were repeated at least
three times with similar results.
For clarity, SD bars were omit-
ted from the graphs, but were
,10% of the value of all points.1347 Griffith et al.
I). Two normal human fibroblast cell types were also tested
for sensitivity to the cytokine-stimulated Mf and were
found to be resistant in all conditions from multiple donors.
Although FasL was not detected on the surface of the ac-
tivated Mf (Fig. 1 A), activated Mf have been shown to
release soluble FasL from intracellular stores (25). There-
fore, to confirm that the observed tumoricidal activity was
specific to TRAIL and not FasL, IFN-g–stimulated Mf
were pretreated with either TRAIL-R2:Fc (35) or Fas:Fc
before adding the tumor cell targets. The TRAIL-R2:Fc
reduced target cell death to control (unstimulated Mf
effector) levels, whereas Fas:Fc did not alter the ability of
the IFN-g–treated Mf to mediate tumor lysis (Fig. 2 D).
Finally, to determine whether Mf NO production con-
tributed to the measured cytotoxic activity, Mf were stim-
ulated as above but in the absence or presence of the NO
synthase inhibitor, L-NMMA (44). The cytotoxic activity
of the IFN-g– and IFN-a–stimulated Mf was not de-
creased in the presence of L-NMMA compared with Mf
stimulated in the absence of the inhibitor (Fig. 2, E and F).
Similar results were observed with other tumor cell targets
(data not shown). Furthermore, analysis of NO production
by the Mf after 12 h stimulation, as measured by the accu-
mulation of nitrite, revealed no increase in nitrite levels in
the culture supernatants with any of the different stimuli
compared with unstimulated Mf (data not shown). Col-
lectively, these results confirm that the TRAIL expressed
on Mf mediates the killing of tumor cells, demonstrating a
novel mechanism of Mf-mediated apoptosis.
TRAIL-expressing Mf Induce Apoptotic Cell Death of Sensi-
tive Tumor Cells. Although the release of 51Cr from the tu-
mor cell targets as measured in Fig. 2 indicates the amount
of cell death, it does not discriminate between apoptotic
and necrotic cell death. Previous reports have demonstrated
that TRAIL-induced cell death occurs through an apop-
totic mechanism (30, 34, 38, 41). To confirm that the tu-
mor cell death induced by the IFN-stimulated Mf was
mediated through an apoptotic mechanism, the binding of
FITC-conjugated annexin V to the tumor cells was ana-
lyzed. Annexin V preferentially binds to phosphatidyl-
serine, a phospholipid component of the inner leaflet of the
plasma membrane that is rapidly externalized during apop-
tosis (45, 46). Upon staining the OVCAR3 tumor cells af-
ter 6 h incubation with unstimulated or cytokine-stimulated
Mf (E/T ratio 2:1) or soluble LZ-TRAIL, only those tumor
cells incubated with IFN-stimulated Mf or LZ-TRAIL
were positive for FITC-annexin V binding (Fig. 3), indi-
cating that these cells were dying from the induction of
apoptosis. Morphological changes (membrane blebbing and
release of apoptotic bodies) were also observed using light
microscopy (data not shown).
Table I. Tumoricidal Activity of Cytokine-stimulated Mf
Tumor cell target
Donors
tested
Mf*
LZ-TRAIL‡ Unstimulated GM-CSF IFN-g IFN-a
H2126 (lung adenocarcinoma) 3 1.3 6 0.9 1.3 6 1.3 47.5 6 4.0 36.1 6 11.9 59.0 6 5.9
PC-3 (prostate carcinoma) 4 3.3 6 2.0 2.0 6 1.7 57.2 6 7.6 41.5 6 5.2 67.5 6 4.2
Colo205 (colon carcinoma) 3 2.3 6 2.1 1.8 6 4.2 46.1 6 3.0 38.4 6 7.1 58.3 6 3.1
OVCAR3 (ovarian carcinoma) 5 5.8 6 4.3 6.3 6 3.8 59.4 6 13.2 47.5 6 7.5 65.4 6 11.0
MDA 231 (breast adenocarcinoma) 3 2.0 6 0.7 2.4 6 0.3 39.6 6 6.8 31.2 6 8.8 57.7 6 10.7
WM 164 (melanoma) 3 0.9 6 0.4 2.4 6 0.8 9.3 6 2.7 4.4 6 2.1 3.2 6 0.9
WM 793 (melanoma) 5 3.6 6 4.2 4.8 6 4.2 45.6 6 14.6 43.7 6 4.5 48.6 6 6.8
Normal lung fibroblasts 2 4.1 6 0.1 4.1 6 2.3 3.2 6 1.3 0.9 6 1.2 1.0 6 1.0
Normal foreskin fibroblasts 2 3.9 6 1.2 3.2 6 2.0 2.9 6 1.0 2.6 6 1.4 2.1 6 1.1
*Mean percent specific lysis (1SD) at 50:1 Mf to target cell ratio.
‡Mean percent specific lysis (1SD) with 1 mg/ml LZ-TRAIL.
Means were calculated from experiments performed with Mf from the indicated number of donors.
Figure 3. Phosphatidylserine
externalization on OVCAR3
tumor cells during apoptosis in-
duced by IFN-stimulated, TRAIL-
expressing Mf. OVCAR3 tumor
cells were cultured for 6 h in
medium alone or in the presence
of LZ-TRAIL (1 mg/ml), unstim-
ulated, or cytokine (GM-CSF,
IFN-g, IFN-a [100 ng/ml for
12 h])–stimulated Mf (E/T ra-
tio 2:1). Cells were then stained
with FITC–annexin V and ana-
lyzed by flow cytometry. The
percent of FITC–annexin V pos-
itive tumor cells is indicated for
each condition. Histograms rep-
resent 104 gated tumor cells.
Similar results were seen with
Mf from three other donors.1348 TRAIL-mediated Tumoricidal Activity by Human Monocytes
The Principal Mechanism of Mf Tumoricidal Activity Differs
after IFN and LPS Stimulation. Having demonstrated that
IFN-stimulated Mf express functional TRAIL, the differ-
ences between TRAIL and TNF-mediated tumoricidal ac-
tivity by Mf were examined. The results presented in Fig.
1 show that TNF was only expressed on Mf after incuba-
tion with LPS. Thus, to demonstrate the biologic activity
of the cell surface TNF detected after LPS stimulation, 2-
and 12-h LPS-stimulated Mf were evaluated for the ability
to kill the TNF-sensitive target cell, L929 (17). In direct
correlation with the flow cytometric results, the 2-h LPS-
stimulated Mf, but not the 12-h LPS-stimulated Mf,
killed L929 target cells to levels comparable to soluble TNF
(Fig. 4 A). When tested for sensitivity to LZ-TRAIL, the
L929 cells were found to be resistant (data not shown).
This killing was TNF-specific as demonstrated by the sig-
nificant inhibition of the lysis of L929 cells upon the addi-
tion of TNFR:Fc, but not TRAIL-R2:Fc (Fig. 4 B). To
further demonstrate that the cytotoxic activity of IFN-
g–stimulated Mf was mediated by TRAIL and not TNF,
tumor cell lysis was measured in the presence of TRAIL-
R2:Fc or TNFR:Fc. Only TRAIL-R2:Fc, and not TNFR:
Fc, inhibited the IFN-g–stimulated Mf from killing the
tumor cell targets (Fig. 4 C). Thus, human Mf have multi-
ple mechanisms for killing a variety of target cells depend-
ing on the activation mechanism.
TRAIL Receptor Expression on Human Mf Is Altered by
IFN. Because TRAIL can interact with two death-induc-
ing and two non-death-inducing receptors, the distribution
of the four known TRAIL receptors on the Mf surface us-
ing receptor-specific mAbs was investigated. Unstimulated
Mf expressed both TRAIL-R2 and -R3, whereas the lev-
els of TRAIL-R1 and -R4 were at or below detection
(Fig. 5 A). However, mRNA for each of the four TRAIL
receptors could be detected by reverse transcription (RT)-
PCR analysis (Fig. 5 B). The kinetics of TRAIL, TRAIL-R2,
and TRAIL-R3 expression after IFN-g stimulation were
then measured at both the protein level by flow cytometry
and the mRNA level by RT-PCR. Increased TRAIL ex-
pression could be detected by 2 h on the cell surface after
addition of IFN-g (Fig. 5 C), whereas RT-PCR analysis
demonstrated that TRAIL mRNA levels increased by 1 h
(Fig. 5 D). No consistent change in TRAIL protein or
mRNA levels was detected after GM-CSF treatment com-
pared with untreated Mf (Fig. 5, C and D).
Examination of the surface levels of TRAIL-R2 and
-R3 during this same 8-h period revealed that IFN-g–stim-
ulated Mf downregulated TRAIL-R2 expression, whereas
TRAIL-R3 was only slightly downmodulated (Fig. 5 C).
In contrast, incubation with GM-CSF for 8 h resulted in a
slight increase in TRAIL-R2 expression. Analysis of mRNA
from IFN-g–stimulated Mf revealed that TRAIL-R2
mRNA levels remained relatively constant over the 8-h pe-
riod, whereas the TRAIL-R2 mRNA levels increased in
Mf stimulated with GM-CSF over time (Fig. 5 D). No
changes in TRAIL-R3 mRNA were observed with IFN-g
or GM-CSF incubation during this period of time (Fig. 5 D),
nor were any changes in TRAIL-R1 or -R4 mRNA or
protein detected (data not shown). Thus, TRAIL expres-
sion can be detected on Mf within 2 h after IFN-g stimu-
lation, paired with a concomitant loss in cell surface expres-
sion of the cognate death-inducing TRAIL-R2. Similar
Figure 4. TNF-mediated apoptosis by human Mf occurs after stimulation
with LPS but not IFN-g. (A) Mf were incubated in the absence or presence
of LPS for 2 or 12 h and then cultured for 8 h with 51Cr-labeled L929 target
cells at the indicated E/T ratios. As a positive control, soluble (s)TNF was
added to targets cells at the indicated concentrations. (B) Inclusion of TNFR:
Fc (20 mg/ml) to 2-h LPS-stimulated Mf inhibited the killing of L929 target
cells, whereas addition of TRAIL-R2:Fc (20 mg/ml) did not. (C) Killing of
WM 793 tumor cells by Mf stimulated with IFN-g for 12 h can be inhibited
by TRAIL-R2:Fc (20 mg/ml), but not TNFR:Fc (20 mg/ml). Data points
represent the mean of triplicate wells, and the experiments were repeated at
least three times with similar results. For clarity, SD bars were omitted from
the graphs, but were ,10% of the value of all points.1349 Griffith et al.
results examining TRAIL and TRAIL receptor expression
on IFN-a–stimulated Mf were also detected (data not
shown).
IFN-stimulated Mf Are Resistant to TRAIL-induced Death.
The loss of TRAIL-R2 expression suggested that periph-
eral blood Mf stimulated with IFN-g would be resistant to
TRAIL-mediated death. Thus, Mf were cultured in the
absence or presence of GM-CSF or IFN-g and then exam-
ined for sensitivity to LZ-TRAIL. Mf treated with GM-CSF
displayed increased sensitivity to TRAIL-induced death
compared with untreated Mf; in contrast, IFN-g treat-
ment significantly decreased TRAIL-induced Mf death
(Fig. 6 A). Similar results were obtained with IFN-a–stim-
ulated Mf (data not shown). No significant changes in Mf
sensitivity to TRAIL were seen with the other cytokines
tested (IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-12,
and IL-15; data not shown) compared with untreated Mf.
These results suggest that Mf stimulated with IFN-g min-
imize TRAIL-mediated suicide or fratricide with the down-
regulation of TRAIL-R2 surface levels. However, it re-
mains possible that additional mechanisms may contribute
to the protection of the Mf from TRAIL-induced death.
The rendering of Mf resistant to TRAIL-mediated apop-
tosis after stimulation with IFN-g suggested that the tumor
cell targets used in Fig. 2 could be affected in a similar fash-
ion upon culture with IFN-g. OVCAR3 tumor cells were
incubated in the absence or presence of IFN-g for 12 h, and
then tested for sensitivity to LZ-TRAIL or IFN-g–stimulated
Mf. In contrast to the Mf, the sensitivity of OVCAR3 tu-
mor cells was not altered after incubation with IFN-g (Fig.
6, B and C). Similar results were seen with other tumor
cells (WM 793 and PC-3; data not shown). These results
imply that not all cell types respond to IFN-g by gain-
ing resistance to TRAIL-induced death as observed with
the Mf.
Discussion
Mf not only influence the activities of other immune
and nonimmune cells in the body, but also function as ef-
fector cells under a variety of conditions (1). Activated Mf
display potent tumoricidal activity against several different
tumor cell types (7, 47–49). The results presented here
demonstrate that one of the mechanisms by which Mf kill
tumor cells is through expression of TRAIL. Mf stimula-
tion with either IFN-g or IFN-a resulted in the rapid ex-
pression of TRAIL on the cell surface, but not FasL or
TNF. Because TRAIL mediates apoptosis in a high per-
centage (approximately two thirds) of hematopoietic and
nonhematopoietic cell types (30, 36, 38, 42), Mf have the
potential to mediate apoptosis of a broad range of tumor
cell types via TRAIL. Expression of TRAIL appeared to be
specific to the IFNs, as Mf stimulation with either IL-1,
IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, or GM-
CSF resulted in no detectable TRAIL expression (data not
shown). Interestingly, a concomitant loss of TRAIL-R2
(and to a lesser extent TRAIL-R3) expression was detected
upon IFN stimulation, rendering the Mf resistant to
TRAIL-mediated death. To our knowledge, this is the first
demonstration of inducible TRAIL expression on a partic-
Figure 5. Surface analysis of IFN-g–stimulated Mf reveals simulta-
neous increase in TRAIL expression with downregulation of TRAIL-R2
expression. (A) Flow cytometric analysis of TRAIL-R1, -R2, -R3, and
-R4 expression on unstimulated Mf. Filled histograms represent staining
by M271 (anti–TRAIL-R1 mAb), M413 (anti–TRAIL-R2 mAb), M430
(anti–TRAIL-R3 mAb), or M444 (anti–TRAIL-R4 mAb), and open his-
tograms represent staining with isotype control mAb. (B) RT-PCR analy-
sis of TRAIL receptor mRNA expression in normal Mf. (C) TRAIL,
TRAIL-R2, and TRAIL-R3 expression after various times of IFN-g
stimulation. Filled histograms represent staining by M413 (anti–TRAIL-
R2 mAb), M430 (anti–TRAIL-R3 mAb), or M181 (anti-TRAIL mAb),
and open histograms represent staining with isotype control mAb. For
comparison, Mf cultured in the absence or presence of GM-CSF for 8 h
were also stained for TRAIL, TRAIL-R2, and TRAIL-R3. (D) RT-
PCR analysis of TRAIL, TRAIL-R2, and TRAIL-R3 mRNA levels
after Mf culture in the absence or presence of IFN-g and GM-CSF.
b-actin was used as a control over the same time course. Similar results
were observed with Mf from two other donors.1350 TRAIL-mediated Tumoricidal Activity by Human Monocytes
ular human peripheral blood cell population, as well as
modulation of the death-inducing TRAIL-R2 by a proin-
flammatory cytokine on the same cell population.
Although the expression of TRAIL on the IFN-stimu-
lated Mf is critical for the tumoricidal activity in our assay
system, the sensitivity of the tumor cell to TRAIL-induced
apoptosis is also an essential component of this phenome-
non, as demonstrated by the fact that the tumor cell lines
and normal cells that were resistant to TRAIL-mediated
apoptosis were also resistant to TRAIL-expressing Mf.
The identification of two TRAIL receptors with death-
inducing ability and two without led to the initial hypothesis
that the expression of TRAIL-R3 and/or -R4 conferred
resistance to TRAIL-induced death (32, 33, 37). However,
it is important to note that this hypothesis was formulated
from reports examining the distribution of TRAIL recep-
tor mRNA in several normal tissues and tumor cell lines
and from experiments where TRAIL-R3 or -R4 was
overexpressed in transfected cells. Most of the tumors used
in this study express TRAIL-R3 and/or -R4 (38, 42).
When the OVCAR3, WM793, and PC3 tumor cells were
cultured with IFN-g before incubation with LZ-TRAIL or
IFN-stimulated Mf, the TRAIL receptor levels remained
unchanged, and no significant change in the level of TRAIL
sensitivity was observed (data not shown). Thus, the differ-
ences in sensitivity of the tumor cells to the TRAIL ex-
pressed on the Mf or the recombinant TRAIL added in so-
lution are probably regulated by a variety of molecular
mechanisms, both inside the cell and at the surface.
While our results focused on the tumoricidal activity of
TRAIL-expressing Mf, previous reports have shown these
cells can also produce cytotoxic inorganic oxidants, such as
NO (10, 11). A role for NO in tumor cell killing has been
documented for both human and mouse activated mac-
rophages (4, 44, 50), where the toxicity of NO is mediated
via mitochondrial damage, inhibition of DNA synthesis,
and disruption of the tricarboxylic acid cycle, ultimately re-
sulting in apoptosis (51, 52). Although murine macro-
phages release high levels of NO after either LPS or IFN-g
stimulation, studies with human peripheral blood Mf have
reported contradictory findings (10). In some reports, Mf
stimulated with either LPS or IFN-g (or in combination)
failed to release significant levels of NO (12–14, 44, 53),
whereas others have reported that IFN-a stimulation re-
sults in a slight increase in NO production (54). In our
studies, addition of the NO inhibitor L-NMMA to the cyto-
toxicity assays did not decrease the ability of the IFN-g–
and IFN-a–stimulated Mf to kill the tumor cell targets.
Moreover, analysis of the culture supernatants for nitrites
revealed no increase after 12 h stimulation with GM-CSF,
IFN-g, or IFN-a (data not shown). These observations,
coupled with the fact that TRAIL-R2:Fc completely in-
hibited the tumoricidal activity of the Mf to background
(unstimulated Mf) levels, imply that TRAIL is the primary
mediator of the tumoricidal activity after IFN stimulation.
Coexpression of TRAIL and TNF, and perhaps other uni-
dentified death-inducing molecules, would theoretically
increase both the cytolytic potential of the Mf and the
range of different tumor targets susceptible to Mf-medi-
ated death.
The importance of IFN in the management of spontane-
ously arising tumors was recently demonstrated in vivo us-
Figure 6. IFN-g stimulation renders Mf resistant to TRAIL-induced
death, but not tumor cell targets. (A) Peripheral blood Mf were incu-
bated for 12 h in the absence or presence of GM-CSF and IFN-g, then
tested for sensitivity to LZ-TRAIL. (B) OVCAR3 tumor cells were in-
cubated for 12 h in the absence or presence of IFN-g, then tested for sen-
sitivity to LZ-TRAIL. (C) OVCAR3 tumor cells were cultured for 12 h
in the absence or presence of IFN-g, then incubated with unstimulated or
IFN-g–stimulated Mf. Percent specific lysis was measured by 51Cr re-
lease after 8 h, and each data point represents the mean of triplicate wells.
For clarity, SD bars were omitted from the graphs, but were ,10% of the
value of all points. These experiments were repeated at least three times
with similar results using Mf from at least three different donors.1351 Griffith et al.
ing mice that lack sensitivity to IFN-g (55). Compared
with wild-type mice, the IFN-g–insensitive mice develop
tumors more rapidly and with greater frequency when
challenged with a chemical carcinogen. Part of this “IFN
effect” is via the interaction of the IFN with the tumor
cells by enhancing the tumor cell tumorigenicity through
heightened MHC class I expression. IFN-g may also en-
hance an innate antitumor mechanism through the induc-
tion of TRAIL on cells of the Mf lineage (55). Although
our data suggest that Mf would confer this antitumor ac-
tivity, further studies are required to determine if other cell
types, such as NK cells, neutrophils, and dendritic cells, are
also able to express TRAIL after IFN stimulation (56).
Finally, in addition to a role in tumoricidal activity, these
data suggest that Mf TRAIL-expression may contribute to
other physiologic and pathologic situations, such as the
AICD of T cells during HIV infection. Recently, Katsikis
et al. (57, 58) have demonstrated that activation-induced
peripheral blood T cell apoptosis in HIV-infected individu-
als was Fas independent, and a potential role for TRAIL in
this phenomenon was identified. It was observed that a
blocking mAb to TRAIL could inhibit the AICD of T cells
in a mixed population of HIV1 PBMCs (58). However, it
was unclear which PBMC subset was expressing TRAIL
and responsible for death of the T cells. Thus, the results
presented here may provide an explanation for these exper-
imental observations, as well as a basis for examining other
activities mediated by activated Mf.
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